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Abstract 
Background: Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. 
Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing 
PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance 
may be lower in men with comorbid conditions. These potential biases may affect PSA-driven 
biopsy rates and subsequent prostate cancer detection in men with high serum cholesterol. Our 
objective was to test the association between serum cholesterol and prostate cancer risk in men 
receiving PSA-independent, study-mandated prostate biopsies. 
Methods: We conducted a post-hoc analysis of data from 4,974 non-statin users in REDUCE, a 
randomized trial in men with elevated PSA and a negative baseline biopsy. Men underwent 2- 
and 4-year trial-mandated prostate biopsies. Associations between baseline serum levels of total 
cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and prostate cancer 
risk, overall and by Gleason grade (<7 vs. ≥7), were examined using multivariable logistic 
regression. 
Results: High total serum cholesterol was associated with an increased risk of high-grade 
prostate cancer diagnosis (ORper10mg/dl 1.05; 95% CI 1.00-1.09; p=0.048), but cholesterol was 
unrelated to either overall or low-grade prostate cancer risk (p-values>0.185). There was no 
association between serum LDL and overall, low- or high-grade prostate cancer risk (p-
values>0.137). In contrast, elevated serum HDL was associated with increased risk of both 
overall (ORper10mg/dl 1.08; 95% CI 1.01-1.16; p=0.033) and high-grade prostate cancer 
(ORper10mg/dl 1.14; 95% CI 1.01-1.28; p=0.034).  
Conclusions: In REDUCE, where all men received PSA-independent, trial-mandated biopsies 
thus ensuring complete prostate cancer ascertainment, high total serum cholesterol and high 
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HDL were associated with increased risk of high-grade prostate cancer, supporting a cholesterol-
prostate cancer link.   
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Introduction 
Obesity is associated with increased risk of several different cancer types, including 
aggressive prostate cancer.1,2 Hypercholesterolemia, an obesity-associated comorbidity,3 
promotes tumor proliferation and inflammation. In addition, cholesterol is the precursor to 
androgens, essential for prostate cancer development and growth.4 Indeed, preclinical studies in 
mouse models of prostate cancer reported increased risk of tumor development and enhanced 
tumor growth in mice fed a cholesterol-enriched diet.5-7 
In contrast, findings from epidemiologic studies examining the association between 
hypercholesterolemia and prostate cancer are conflicting. While some found high cholesterol to 
be associated with increased risk of both overall and high-grade prostate cancer,8,9 others 
reported inverse associations,10 and a recent meta-analysis reported no significant association 
between total cholesterol, high-density lipoprotein (HDL), or low-density lipoprotein (LDL) and 
risk of overall or high-grade prostate cancer.11 Two potential sources of bias may have 
influenced prior study findings. Serum cholesterol is positively correlated with serum prostate-
specific antigen (PSA),12,13 potentially leading to increased PSA-driven biopsy rates and more 
prostate cancer diagnoses among men with high cholesterol. Conversely, obesity-associated 
comorbidities including hypercholesterolemia have been associated with lower biopsy 
compliance,14,15 potentially leading to fewer prostate cancer diagnoses among men with high 
cholesterol. 
To minimize the contribution of these potential biases, we tested the association between 
serum cholesterol and prostate cancer risk using data from REduction by DUtasteride of prostate 
Cancer Events (REDUCE), a randomized trial where all men received prostate biopsies 
regardless of PSA or other clinical factors. Given preclinical data linking cholesterol to the 
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development and progression of prostate cancer,5 we hypothesized that elevated serum 
cholesterol would be associated with increased risk of prostate cancer.   
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Patients and Methods 
Study design 
REDUCE, a prostate cancer chemoprevention trial, randomized men to dutasteride vs. 
placebo.16 Eligible men were 50-75 years old, with a PSA of 2.5-10.0 ng/ml if 50-60 years or 
3.0-10.0 ng/ml if >60 years, and had a single, negative study-independent prostate biopsy (6-12 
cores) within 6 months prior to enrollment. Ineligible men had a past history of prostate cancer, 
prostate surgery, prostate volume >80ml, or International Prostate Symptom Score >25 or >20 on 
alpha-blockers. Trial-mandated ten-core transrectal ultrasound (TRUS)-guided prostate biopsies 
were performed at 2- and 4-years post randomization regardless of PSA. Protocol-independent 
biopsies were performed at the physician’s discretion. High density lipoprotein (HDL), low 
density lipoprotein (LDL), and total cholesterol were measured by Quest Diagnostic (Van Nuys, 
California, USA) at the baseline study visit, after enrollment but before randomization.  
Participants 
REDUCE enrolled 8,122 men in the efficacy population. We excluded men with missing 
baseline data on race (n=1), body mass index (BMI; n=131), PSA (n=18), digital rectal exam 
(DRE) findings (n=9), history of coronary artery disease (CAD; n=2), family history of prostate 
cancer (n=6), smoking status (n=3), diabetes (n=1), alcohol use (n=40), total cholesterol (n=151), 
and LDL (n=189). While baseline statin data were available, we were unable to control for 
duration of statin use before enrollment or for continued statin use during the trial; therefore, we 
excluded men using statins (n=1,335) and/or other lipid-lowering therapy (n=134) at baseline. 
Differences in baseline characteristics in REDUCE by statin use have been previously 
published.17 As baseline HDL and cholesterol did not follow parametric distributions, 129 men 
with HDL or cholesterol values ≥ three standard deviations outside the mean were excluded. 
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Finally, of the remaining 5,973 men, a further 999 were excluded who did not receive any on-
study biopsies, leaving a study population of 4,974. 
Statistical Analysis 
We examined associations between each lipid type and risk of prostate cancer diagnosis, 
treating lipids as both continuous and categorical variables, with categories defined using 
National Cholesterol Education Program Adult Treatment Panel III guidelines.18 Our primary 
exposure was total serum cholesterol, with HDL and LDL treated as secondary exposure 
variables. As not all men in the efficacy population received both the 2- and 4-year trial-
mandated biopsies, we explored the association between demographic and clinical characteristics 
and biopsy compliance. Total serum cholesterol level was not associated with biopsy compliance 
at the 2-year biopsy. As such, to ensure all men had equal opportunity for prostate cancer 
diagnosis regardless of cholesterol level, we considered the 2-year biopsy as our primary 
outcome, among men who received the 2-year biopsy.  
Differences in baseline demographic and clinical characteristics across cholesterol 
categories were tested using ANOVA, Kruskal-Wallis and χ² for continuous parametric, 
continuous non-parametric and categorical variables respectively. We tested the relationship 
between continuous serum cholesterol, LDL and HDL levels using Pearson’s correlation. 
Logistic regression was used to examine associations between lipids and prostate cancer risk, 
adjusting for baseline age (continuous), race (white, non-white), BMI (continuous), PSA 
(continuous), DRE findings (normal, abnormal), CAD history (yes, no), family history of 
prostate cancer (yes, no), smoking status (current, former, never), diabetes (yes, no), alcohol use 
(none, ≤7 units/week, >7 units/week), region (North America, Europe, other), and treatment arm 
(placebo, dutasteride). Given weak correlations between total cholesterol, LDL and HDL 
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(Supplementary Table 1), we mutually adjusted analyses for other lipid types. Continuous lipid 
levels were presented in 10 mg/dL increments to aid interpretation of odds ratios.  
We used multinomial logistic regression to examine the relationship between lipids and 
prostate cancer risk by disease grade, adjusting for aforementioned covariates. High-grade 
prostate cancer was defined as Gleason score ≥7, and low-grade prostate cancer as Gleason score 
<7, as previously published in REDUCE.17 Given the potential interaction between treatment 
arm and lipids in predicting risk of prostate cancer diagnosis, we tested whether randomization to 
placebo vs. dutasteride was a significant effect modifier of the association between lipids and 
prostate cancer risk by incorporating a cross product term along with the primary variables in the 
multivariable analysis.  
Statistical significance was defined as p<0.05. All analysis was performed using Stata 
v13.1 (StataCorp, College Station, TX USA).  
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Results 
Patient demographics 
Average baseline serum cholesterol level was 222.5 mg/dL. Men with higher cholesterol 
were older (p=0.002), more likely to be white (p=0.001) and European (p<0.001), had a higher 
BMI (p<0.001), and were more likely to have diabetes (p<0.001). Men with high cholesterol had 
lower alcohol intake (p=0.010) and were less likely to have a family history of prostate cancer 
(p=0.004). No significant associations were seen between serum cholesterol and baseline PSA, 
history of CAD, smoking status or treatment arm (Table 1).  
Biopsy compliance 
Non-white race (p=0.035), North American location (p=0.001), low baseline LDL 
(p=0.043) and randomization to the placebo arm (p=0.042) were associated with lower 
likelihood of receiving at least one on-study biopsy. Baseline HDL, cholesterol, BMI, PSA, 
history of CAD, baseline DRE findings, and baseline age were unrelated to biopsy compliance 
(data not shown). However, among men with a negative 2-year biopsy, those with high 
cholesterol were less likely to receive the 4-year biopsy (p=0.023). Given this, we selected 
prostate cancer risk at the 2-year biopsy as our primary endpoint, as cholesterol was not 
significantly associated with compliance at the study-mandated 2-year biopsy (p=0.408). Risk of 
prostate cancer diagnosis at any time during the study period was examined as a secondary 
outcome. 
Interaction between lipids and treatment arm in predicting prostate cancer risk 
We found similar associations between total cholesterol and overall prostate cancer risk 
in both arms (p-interaction=0.091). Similarly, there was no significant interaction between total 
serum cholesterol and treatment arm for the outcomes of low- or high-grade prostate cancer (all 
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p-interactions≥0.103), and no interactions between HDL or LDL and treatment arm for overall, 
low-, or high-grade prostate cancer (all p-interactions≥0.433). As such, both arms were 
combined for all analyses. 
Relationship between total serum cholesterol and prostate cancer risk  
There were no significant associations between total serum cholesterol categories and 
risk of overall, low- or high-grade prostate cancer at the 2-year biopsy on univariable or 
multivariable analysis (all p-values ≥0.185; Table 2). However, there was a significant positive 
relationship between continuous cholesterol levels and risk of high-grade prostate cancer at the 
2-year biopsy in univariable (ORper 10mg/dL 1.05; 95% CI 1.01-1.09; p=0.019) and multivariable 
analysis (ORper 10mg/dL 1.05; 95% CI 1.00-1.09; p=0.048). No significant association was seen 
between continuous cholesterol level and risk of overall or low-grade prostate cancer. 
Further analysis was performed to examine the relationship between serum cholesterol 
and risk of prostate cancer diagnosis at any biopsy during the study period, recognizing that 
patients with elevated cholesterol were less likely to receive the study-mandated 4-year biopsy 
(thus reducing the opportunity to have prostate cancer diagnosed). In this setting, no significant 
association was seen between cholesterol and prostate cancer risk on either univariable or 
multivariable analysis, regardless of whether cholesterol was modeled as a continuous or 
categorical variable (all p-values ≥0.401; Supplementary Table 2). Furthermore, when stratified 
by disease grade, no significant relationship between cholesterol and low- or high-grade prostate 
cancer risk was seen (all p-values ≥0.097). 
Relationship between serum HDL and LDL and prostate cancer risk 
Serum LDL was not associated with overall prostate cancer risk at the 2-year biopsy on 
univariable or multivariable analysis (all p-values ≥0.218; Table 3). When stratified by disease 
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grade, no significant associations were seen between categorical or continuously-coded LDL and 
low- or high-grade prostate cancer risk (all p-values ≥0.137; Table 3). When examining the 
association between LDL and risk of prostate cancer diagnosis at any time during the study 
period, similar null findings were seen (Supplementary Table 3). 
In contrast to relatively null findings for LDL, HDL was positively associated with a 
higher risk of overall prostate cancer on both univariable (p<0.004) and multivariable analysis 
(ORper 10mg/dL 1.08; 95% CI 1.01-1.16; p=0.033). When stratified by disease grade, on 
multivariable analysis, each 10 mg/dL increase in HDL was associated with an increased risk of 
high-grade prostate cancer (ORper 10mg/dL 1.14; 95% CI 1.01-1.28; p=0.034). HDL was associated 
with an increased risk of low-grade prostate cancer in univariable analysis (OR per 10mg/dL 1.08; 
95% CI 1.00-1.17; p=0.040), but this association was not significant on multivariable analysis 
(OR per 10mg/dL 1.06; 95% CI 0.97-1.14; p=0.197). Similar patterns of association were seen 
between HDL and prostate cancer diagnosed at any point during the study period 
(Supplementary Table 3).   
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Discussion 
Cholesterol as a risk factor for prostate cancer remains controversial. Despite pre-clinical 
data showing a role for serum cholesterol in prostate cancer growth, results from epidemiologic 
studies are mixed. We tested the association between serum cholesterol and risk of prostate 
cancer diagnosis in REDUCE, where men with a negative baseline prostate biopsy underwent 
trial-mandated, PSA-independent biopsies at 2- and 4-years. Our findings demonstrate an 
association between high serum cholesterol and HDL and increased risk of high-grade prostate 
cancer in a setting where trial-mandated biopsies ensured complete cancer ascertainment. These 
data support a role for cholesterol, a modifiable risk factor, in aggressive prostate cancer. 
Prostate cancer is unique in its dependence on androgens for growth.19 Cholesterol is the 
precursor for androgen synthesis by the prostate, leading to the hypothesis that increased serum 
cholesterol levels may be associated with a higher prostate cancer risk. Zhuang et al showed that 
a cholesterol-enriched diet promoted tumor growth in a xenograft mouse model of prostate 
cancer, compared to control diet.5 Another study showed that lowering serum cholesterol in 
xenograft mouse model of prostate cancer reduced tumor androgen concentrations and slowed 
tumor growth.20 In contrast to these pre-clinical data supporting a cholesterol-prostate cancer 
link, findings from epidemiologic studies remain mixed. Analysis of the placebo arm of the 
Prostate Cancer Prevention Trial (PCPT) showed reduced risk of high-grade prostate cancer in 
men with lower cholesterol levels,9 and a study from the Veterans Administration found that 
high serum cholesterol was associated with increased high-grade prostate cancer risk.21 An 
association between high serum cholesterol and increased prostate cancer risk is also supported 
by results from the Finnish Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) 
cohort.8 However, a meta-analysis of these and other studies reported no significant association 
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between serum cholesterol and risk of either overall or high-grade prostate cancer.22 Given that 
past studies were conducted during the PSA-screening era, it is possible that their results were 
affected by the positive correlation between cholesterol and PSA.12,13 Factors influencing PSA 
levels may affect PSA-driven recommendations for prostate biopsy thereby influencing biopsy 
rates. Moreover, observational studies are rarely able to control for biopsy compliance, which 
differs by obesity and obesity-associated co-morbidity status.14,15 Data from the PCPT 
chemoprevention trial that, like REDUCE, implemented trial-mandated PSA-independent 
biopsies, showed that men with low serum cholesterol had lower high-grade prostate cancer risk. 
As such, our study builds on evidence for a cholesterol-prostate cancer link in the context of 
PSA-independent, trial-mandated biopsies where all men had equal opportunity for prostate 
cancer diagnosis. 
Relatively few studies have examined the association between HDL and prostate cancer 
risk, reporting mixed findings. A Swedish cohort including ~1,500 prostate cancer cases found 
that high HDL was inversely associated with overall prostate cancer risk.23 An analysis of the 
Finnish ATBC cohort also reported an inverse association between HDL level and risk of 
prostate cancer,8 while a study of the US Veterans Administration reported that high HDL was 
associated with increased risk of overall and high-grade prostate cancer.21 However, a meta-
analysis of these and a number of other null studies reported no significant association between 
serum HDL and prostate cancer risk.22 Given anti-inflammatory, anti-proliferative and anti-
oxidant properties of HDL,24 it is unclear why high HDL would be associated with an increased, 
and not decreased, risk of prostate cancer, as we found in the present study. However, as some 
data are now challenging the long-hypothesized cardio-protective role of HDL,25 alongside a 
meta-analysis showing that drugs increasing HDL do not reduce cardiovascular risk further 
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questioning the health “benefits” of higher HDL,26 further study is needed to define the link 
between high HDL and increased risk of prostate cancer.  
Our findings should be considered in the context of the strengths and weaknesses of this 
study. First, eligibility criteria for REDUCE ensured that all men had baseline PSA levels 
between 2.5 and 10 ng/ml. In addition, various exclusion criteria in REDUCE increased the 
homogeneity of the sample, but may limit the generalizability of our results. Second, serum 
cholesterol levels were assessed at a single time point and therefore do not capture any potential 
variability in cholesterol levels over time. However, the optimal timing or “window of 
susceptibility” for prostate cancer development to be influenced by serum cholesterol is not 
known. Moreover, any exposure misclassification would likely be non-differential between 
groups and therefore bias our results towards the null. Third, we found that high total serum 
cholesterol and HDL, both coded as continuous variables, were associated with increased risk of 
high-grade prostate cancer, while National Cholesterol Education Program-defined categories of 
cholesterol and HDL were not significantly associated with high-grade prostate cancer risk. 
However, the thresholds at which serum cholesterol could influence prostate cancer risk may be 
different than those established for cardiovascular disease risk and therefore continuous levels 
may provide a more appropriate measure of exposure in the context of prostate cancer risk. 
Fourth, although we excluded men using statins at baseline, some men may have initiated statin 
use during the trial period. However, for these men, our lipid measures were taken prior to statin 
use. Moreover, any statin-mediated changes in lipids during the trial period would likely bias our 
results towards the null given the inverse association between statins and aggressive prostate 
cancer risk 27. Finally, although we were able to adjust our models for a number of potential 
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confounders, we lacked data on diet and physical activity. Study strengths include the large, 
multinational population in REDUCE, and PSA-independent on-study biopsies.  
In conclusion, using data from the REDUCE trial, where men underwent PSA-
independent prostate biopsies, we found that high total serum cholesterol and high HDL were 
associated with increased risk of high-grade prostate cancer. Together with findings from PCPT, 
another trial which implemented mandatory PSA-independent biopsies, our results support an 
association between serum cholesterol and increased risk of high-grade prostate cancer where 
PSA-independent, trial-mandated biopsies ensured that all men had equal opportunity for 
prostate cancer detection. These findings, combined with evidence that use of the cholesterol-
lowering statins is associated with reduced risk of high-grade prostate cancer, suggest that serum 
lipid levels should be explored as modifiable risk factors for aggressive prostate cancer. 
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Table 1: Baseline characteristics of the REDUCE study population according to total serum 
cholesterol levels. 
 Total serum cholesterol level  
 Normal 
(<200 mg/dL) 
Borderline 
(200-239 
mg/dL) 
High 
(≥240 mg/dL) 
p-
value* 
Total patients, n (%) 1,037 (20.9) 2,948 (59.3) 989 (19.9)   
Age, mean (SD) 62.3 (6.2) 62.4 (5.9) 63.4 (5.9) 0.002† 
Race, n (%)     
   White 918 (88.5) 2,718 (92.2) 913 (92.3) 0.001 
   Non-white 119 (11.5) 230 (7.8) 76 (7.7) 
Region (%)     
   North America 272 (26.2) 575 (19.5) 127 (12.8) <0.001 
   Europe 576 (55.5) 1,903 (64.6) 739 (74.7) 
   Other 189 (18.2) 470 (15.9) 123 (12.4) 
Body mass index (kg/m2), 
median (IQR) 
26.0 (24.0-
28.4) 26.7 (24.7-29.0) 
27.4 (25.2-
29.9) 
<0.001†
† 
PSA (ng/ml), median (IQR) 5.7 (4.4-7.4) 5.8 (4.4-7.4) 5.7 (4.4-7.4) 0.922†† 
Abnormal DRE, n (%) 49 (4.7) 88 (3.0) 28 (2.8) 0.017 
History of CAD, n (%) 44 (4.2) 157 (5.3) 51 (5.2) 0.389 
Family history of prostate 
cancer, n (%) 
153 (14.8) 369 (12.5) 98 (9.9) 0.004 
Smoking history, n (%)     
   Never 498 (48.0) 1,398 (47.4) 452 (45.7) 0.071 
  
     Former 361 (34.8) 1,130 (38.3) 392 (39.6)    Current 178 (17.2) 420 (14.3) 145 (14.7) 
Diabetes, n (%)     
   No 1,005 (97) 2,876 (98) 824 (83) <0.001 
   Yes 32 (3) 72 (2) 165 (17) 
Alcohol intake, n (%)     
   None 297 (29) 682 (23) 231 (23) 0.010 
   ≤7 units per week 488 (47) 1,486 (50) 497 (50) 
   >7 units per week 252 (24) 780 (26) 261 (16) 
Treatment (%)     
   Placebo 541 (52.2) 1,496 (50.8) 511 (51.7) 0.698 
   Dutasteride 496 (47.8) 1,452 (49.3) 478 (48.3) 
Abbreviations: PSA (prostate specific antigen), SD (standard deviation), IQR (interquartile 
range, Q1-Q3), DRE (digital rectal exam), CAD (coronary artery disease) 
*P value by χ², except where noted; †P value by ANOVA; †† P value by Kruskal-Wallis 
Table 2: Associations between total serum cholesterol levels and prostate cancer risk at the 2-year biopsy in REDUCE 
 Overall prostate cancer  Low-grade prostate cancer High-grade prostate cancer 
 OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Total cholesterol              
Unadjusted       
         Normal 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - 
         Borderline 0.87 (0.71-1.07) 0.185 0.88 (0.70-1.11) 0.289 0.85 (0.59-1.22) 0.373 
         High 0.96 (0.75-1.23) 0.741 0.84 (0.63-1.13) 0.261 1.24 (0.82-1.88) 0.297 
      Per 10 mg/dl 1.01 (0.99-1.04) 0.255 1.00 (0.97-1.03) 0.920 1.05 (1.01-1.09) 0.019 
Adjusted*             
         Normal 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - 
         Borderline 0.88 (0.72-1.09) 0.243 0.89 (0.70-1.13) 0.334 0.87 (0.60-1.26) 0.465 
         High 0.94 (0.72-1.23) 0.656 0.83 (0.61-1.14) 0.246 1.23 (0.79-1.90) 0.366 
      Per 10 mg/dl 1.01 (0.99-1.04) 0.347 1.00 (0.97-1.03) 0.895 1.05 (1.00-1.09) 0.048 
*adjusted for age, race, geographic region, PSA, BMI, baseline DRE, family history of prostate cancer, coronary artery disease, 
smoking status, diabetes, alcohol use, treatment group, LDL level and HDL level 
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Table 3: Association between serum levels of LDL and HDL and prostate cancer risk at the 2-year biopsy in REDUCE 
 Overall prostate cancer risk Low-grade prostate cancer High-grade prostate cancer 
 OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
LDL†                  
Unadjusted          
         Normal 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - 
         Borderline 1.05 (0.80-1.37) 0.723 1.23 (0.88-1.71) 0.229 0.77 (0.51-1.18) 0.233 
         High 0.92 (0.68-1.24) 0.567 1.05 (0.73-1.51) 0.809 0.71 (0.44-1.15) 0.165 
      Per 10 mg/dl 0.99 (0.97-1.02) 0.451 1.00 (0.97-1.02) 0.749 0.98 (0.94-1.02) 0.345 
Adjusted*                
         Normal 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - 
         Borderline 1.04 (0.79-1.37) 0.769 1.19 (0.85-1.66) 0.311 0.80 (0.52-1.24) 0.326 
         High 0.86 (0.63-1.18) 0.347 0.97 (0.67-1.42) 0.886 0.68 (0.42-1.13) 0.137 
      Per 10 mg/dl 0.98 (0.96-1.01) 0.218 0.99 (0.96-1.02) 0.433 0.98 (0.93-1.02) 0.260 
HDL††             
Unadjusted       
         Low 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - 
         Borderline 1.20 (0.96-1.50) 0.106 1.17 (0.90-1.51) 0.235 1.28 (0.86-1.90) 0.219 
         Normal 1.30 (0.99-1.69) 0.055 1.24 (0.91-1.70) 0.167 1.43 (0.90-2.28) 0.130 
      Per 10 mg/dl 1.10 (1.03-1.17) 0.004 1.08 (1.00-1.17) 0.040 1.14 (1.02-1.27) 0.017 
Adjusted*            
         Low 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - 
         Borderline 1.17 (0.93-1.47) 0.176 1.12 (0.86-1.46) 0.397 1.31 (0.87-1.97) 0.197 
         Normal 1.19 (0.90-1.58) 0.215 1.12 (0.81-1.55) 0.490 1.39 (0.85-2.28) 0.190 
      Per 10 mg/dl 1.08 (1.01-1.16) 0.033 1.06 (0.97-1.14) 0.197 1.14 (1.01-1.28) 0.034 
*adjusted for age, race, geographic region, PSA, BMI, DRE, family history of prostate cancer, coronary artery disease, smoking 
status, diabetes, alcohol use, treatment group, total cholesterol level 
†LDL analysis additionally adjusted for HDL level 
††HDL analysis additionally adjusted for LDL level 
